CELL INTELLIGENCE · 肿瘤细胞治疗研究

IL-15 在固有免疫与适应性免疫界面的反式呈递：机制及其在肿瘤免疫治疗中的转化

IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.

免疫检查点抑制剂适应症的扩展：十年成功势头强劲

Expanding indications of immune checkpoint inhibitors: a decade of success going strong.

自 2011 年以来，ICIs 几乎渗透到肿瘤学的所有领域，对多种癌症类型产生了有意义的影响。除了扩大适应症外，它们还为许多应答者提供了持久获益的潜力。在黑色素瘤、头颈部、肾脏、肝脏和尿路上皮癌中，临床试验之外的 PD-L1 检测已不再需要。PD-1 ± CTLA-4 抑制在微卫星不稳定性高癌症中的肿瘤不可知疗效已得到充分确立。在其他癌症亚群中获益有限，这凸显了生物标志物发现和治疗策略优化的必要性，包括在 ICIs 基础上加用抗体-药物

病例报告：致敏树突状细胞免疫治疗用于多种实体瘤

Case Report: Primed dendritic cell immunotherapy for multiple solid tumors.

靶向 MUC16 的膀胱内间皮素 CAR-T 细胞在临床前模型中有效控制膀胱癌

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

Bel-sar 在中危和高危非肌层浸润性膀胱癌患者中的早期疗效和探索性生物标志物数据

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

巨细胞尿路上皮癌：形态学测量见解及其与侵袭性临床特征的关联

Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features.

铂类治疗的晚期肌层浸润性尿路上皮癌中的肿瘤 B 细胞浸润

Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.

PETIL：预测膀胱癌过继细胞免疫治疗中 TIL（肿瘤浸润淋巴细胞）的扩增

PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers.

虚拟队列框架及其在膀胱癌过继性细胞治疗中的应用

A virtual cohort framework with applications to adoptive cell therapy in bladder cancer.

唾液酸结合脂质体纳米颗粒用于靶向膀胱癌治疗

Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.